Recent Updates
Recently added Catalysts

TERN-501

Phase 2

NASH - Nonalcoholic Steatohepatitis | Small molecule | Metabolic |Terns Pharmaceuticals, Inc.|Last Updated: Mar 11, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment162
FDA Designations
No designations recorded
Clinical trial landscape

TERN-501 · 1 trial · 1 indication

Phase 2 1
NCT05415722DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic SteatohepatitisNASH - Nonalcoholic Steatohepatitis
COMPLETED162 Analytics
PHASE2COMPLETED
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
NASH - Nonalcoholic Steatohepatitis
NCT05415722162
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
TERN-501DRUGInvestigational drug
TERN-101DRUGInvestigational drug
PlaceboOTHERMatching placebo
Unlock Study Design Details